TENX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TENX is not a good buy right now for an impatient buyer. The stock is in a bearish downswing (weak momentum, recent -6.43% regular-session drop) with no Intellectia buy signals today and no near-term news catalyst; the more compelling upside is tied to a pivotal readout expected in 2H next year, which doesn’t fit an “buy now, want it to move soon” profile.
Price/Trend: Sharp near-term weakness (regular session -6.43%; post-market ~12.51) puts price below the pivot (14.612) and near key supports (S1 12.901; S2 11.844). This is a downtrend/downswing setup until price reclaims the pivot area. Momentum: MACD histogram -0.452 and negatively expanding = bearish momentum still increasing (not yet stabilizing). RSI: RSI(6) ~27.3 = oversold/washed-out conditions, which can spark bounces, but oversold alone is not a buy signal when MACD continues to deteriorate. Moving averages: Converging MAs = transition/indecision, but current momentum favors bears. Levels: Immediate resistance is the pivot ~14.61; further resistances R1 16.32 and R2 17.38. If S1/S2 fail, downside risk grows quickly. Pattern-based odds (provided): 30% chance of about -1.39% next day, -1.34% next week, and +7.56% next month—suggesting near-term headwinds with a possible mean-reversion bounce later.
Intellectia Proprietary Trading Signals
Analyst catalyst: Guggenheim reiterated Buy and raised price target to $25 (from $14), calling TENX a Top Pick for 2026 as it approaches a first pivotal readout for oral levosimendan in pulmonary hypertension caused by HFpEF (expected 2H next year).
Technical: Oversold RSI increases odds of a short-term reflex bounce if support holds.
implies continued dependence on clinical milestones/financing.
Latest quarter: 2025/Q3. Revenue remained at 0 (no YoY growth). Net income was -$15.804M (improved YoY by 299.04% per provided figures), and EPS was -0.40 (improved YoY by 110.53%). Overall: losses are still substantial and the business appears pre-revenue; improvement is directionally positive but not yet a durable growth trend.
Recent Street view (limited to provided data): On 2025-12-17, Guggenheim maintained a Buy and raised the price target to $25 from $14, citing the upcoming pivotal readout in 2H next year. Wall Street pros: Clear event-driven upside if the pivotal data are positive; acknowledged as a high-upside catalyst setup. Wall Street cons: Timing is long-dated (next year), and current price action is weak; without nearer-term catalysts, shares can keep sliding or chopping despite bullish long-term targets. Politicians/Influential trading: No recent congress trading data available in the last 90 days.
